ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
In connection with remarks to be made at the J.P. Morgan Virtual 40th Annual
Healthcare Conference on Monday, January 10, 2022, beginning at 10:30 a.m.
(Eastern Time), DexCom, Inc. ("DexCom") Chairman, President and Chief Executive
Officer Kevin Sayer will report that preliminary, unaudited revenue for the
fourth quarter ended December 31, 2021 is expected to be approximately $698
million, an increase of 23% over the fourth quarter of 2020. For fiscal 2021,
total preliminary, unaudited revenue is expected to be approximately $2.448
billion, an increase of more than 27% over 2020.
Finally, Mr. Sayer will provide DexCom's initial financial outlook for fiscal
year 2022, including an anticipated range for total revenue of $2.82 billion to
$2.94 billion.
The fourth quarter and fiscal year 2021 preliminary unaudited financial results
contained in Mr. Sayer's presentation and in this report are subject to
finalization in connection with the preparation of DexCom's Annual Report on
Form 10-K for the twelve months ended December 31, 2021. This report contains,
and Mr. Sayer's presentation on January 10, 2022 will contain, forward-looking
statements concerning DexCom's or its management's intentions, beliefs,
expectations and strategies for the future, including those related to DexCom's
preliminary, unaudited revenue for the fourth quarter and the full fiscal year
2021, estimated revenue for fiscal 2022. Because such statements deal with
future events, they are subject to various risks and uncertainties. The risks
and uncertainties that may cause actual results to differ materially from
DexCom's current expectations are more fully described in DexCom's Annual Report
on Form 10-K for the period ended December 31, 2020, as filed with the
Securities and Exchange Commission on February 11, 2021, its most recent
Quarterly Report on Form 10-Q for the period ended September 30, 2021, as filed
with the Securities and Exchange Commission on October 28, 2021, and its other
reports, each as filed with the Securities and Exchange Commission. All
forward-looking statements and reasons why results might differ included in this
Current Report are made as of the date of this Current Report, based on
information currently available to DexCom. Should one or more of these risks or
uncertainties materialize, or should any of DexCom's assumptions prove
incorrect, actual results may vary in material respects from those projected in
these forward-looking statements. DexCom undertakes no obligation to publicly
update or revise any forward-looking statements or reasons why results might
differ.
In connection with Mr. Sayer's presentation, on January 10, 2022, DexCom issued
a press release announcing preliminary, unaudited revenue for the fourth quarter
of 2021 and fiscal year 2021, initial financial outlook for fiscal year 2022,
and certain other information, which is attached here as Exhibit 99.01.
The information in this Item 2.02, including Exhibit 99.01 hereto, is furnished
pursuant to Item 2.02 of Form 8-K, and is not deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that section. The information contained herein and in the
accompanying exhibit is not incorporated by reference in any filing of DexCom
under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether
made before or after the date hereof and irrespective of any general
incorporation language in any filings.
ITEM 8.01. OTHER EVENTS.
In connection with his remarks to be made at the J.P. Morgan Virtual 40th Annual
Healthcare Conference Mr. Sayer also presented clinical data on DexCom's next
generation interoperable CGM, drawn from the company's U.S. pivotal trial,
reporting summary mean absolute relative difference (MARD) as 8.2% in adults and
8.1% in pediatrics.
--------------------------------------------------------------------------------
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
Number Description
99.01 Press release dated January 10, 2022 announcing the financial results
for the quarter ended December 31, 2021 and certain other information.
104 Cover Page Interactive Data File (formatted as Inline XBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses